BALTIMORE, MD--(Marketwired - August 10, 2016) - Terbium Labs, the company behind Matchlight, the world's first fully private, fully automated, data intelligence system, today announced that its dark ...

Forgive my little foolishness but I do like to go back to past claims of how everything is running out and measuring them up against reality. And here's something from the New Scientist published back ...

A collaboration between the Paul Scherrer Institute, CERN's ISOLDE facility, and the Institut Laue-Langevin, has published preclinical study results for a newly developed set of tumour-targeting ...

Terbium-161 has a decisive advantage over lutetium-177: in addition to beta particles, it also emits conversion and Auger electrons. "This radiation has a range of less than one micrometer, or one ...

If you can get rid of circulating tumor cells and tumor cell clusters that detach from a tumor, spreading the disease in the body, cancer is less likely to return. This is the hope behind a ...

BALTIMORE, June 15, 2021 /PRNewswire/ -- Deloitte announced today its acquisition of substantially all of the assets of Terbium Labs, a Baltimore-based digital risk protection company that helps ...

eSpeaks’ Corey Noles talks with Rob Israch, President of Tipalti, about what it means to lead with Global-First Finance and how companies can build scalable, compliant operations in an increasingly ...

Federal Hill-based Terbium Labs raised $2 million in new funding from the Omidyar Network, the philanthropic investment firm started by eBay founder Pierre Omidyar and Pam Omidyar, said Terbium CEO ...

Terbium-161 NCA is a no-carrier-added, neutron-activated radionuclide uniquely suited for Radio Ligand Therapy (RLT). With an abundant emission of Auger electrons and high Linear Energy Transfer (LET) ...

Nanoparticles are ultra fine particles having one or more dimensions of the order of 100 nm or less. The properties of nanoparticles differ completely from that of bulk materials. Therefore, the ...

The radiopharmaceutical consists of a radioactive molecule – in this case terbium-161 linked to a ligand. This ligand recognises proteins on the tumour cell, allowing highly targeted cancer treatment.